Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesLiabilities and Shareholders EquityNon-Current AssetsNon-Current Deffered RevenueOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesReceivables - NetRetained EarningsShareholder's EquityShares OutstandingTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Sutro Biopharma (STRO) Non-Current Assets (2017 - 2025)

Historic Non-Current Assets for Sutro Biopharma (STRO) over the last 9 years, with Q3 2025 value amounting to $27.5 million.

  • Sutro Biopharma's Non-Current Assets fell 4018.85% to $27.5 million in Q3 2025 from the same period last year, while for Sep 2025 it was $136.2 million, marking a year-over-year decrease of 2818.41%. This contributed to the annual value of $43.9 million for FY2024, which is 1076.76% down from last year.
  • Latest data reveals that Sutro Biopharma reported Non-Current Assets of $27.5 million as of Q3 2025, which was down 4018.85% from $30.7 million recorded in Q2 2025.
  • Sutro Biopharma's 5-year Non-Current Assets high stood at $122.9 million for Q4 2021, and its period low was $27.5 million during Q3 2025.
  • Moreover, its 5-year median value for Non-Current Assets was $52.9 million (2023), whereas its average is $59.9 million.
  • Its Non-Current Assets has fluctuated over the past 5 years, first soared by 70824.02% in 2021, then crashed by 5622.94% in 2022.
  • Over the past 5 years, Sutro Biopharma's Non-Current Assets (Quarter) stood at $122.9 million in 2021, then plummeted by 56.23% to $53.8 million in 2022, then decreased by 8.55% to $49.2 million in 2023, then dropped by 10.77% to $43.9 million in 2024, then crashed by 37.25% to $27.5 million in 2025.
  • Its Non-Current Assets stands at $27.5 million for Q3 2025, versus $30.7 million for Q2 2025 and $34.0 million for Q1 2025.